TY - JOUR
T1 - Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia
AU - Roberts, Kandice E.
AU - Deininger, Michael W.
AU - Hildebrandt, Gerhard C.
AU - Gackenbach, Brian K.
AU - Krem, Maxwell M.
N1 - Funding Information:
GCH reports research support from Takeda, Pharmacyclics, Jazz, Astellas, and Incyte and stock ownership of Bristol-Myers Squibb. MWD reports research support from NIH, R01CA178397.
PY - 2020
Y1 - 2020
UR - http://www.scopus.com/inward/record.url?scp=85089783902&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089783902&partnerID=8YFLogxK
U2 - 10.1080/10428194.2020.1808210
DO - 10.1080/10428194.2020.1808210
M3 - Letter
C2 - 32835547
AN - SCOPUS:85089783902
SN - 1042-8194
VL - 61
SP - 3507
EP - 3510
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 14
ER -